Ichnos Glenmark Plans ISB 2001 Data at ASH
Updated clinical data for the trispecific ISB 2001 in relapsed or refractory multiple myeloma will be presented at the 68th ASH Annual Meeting.
Updated on Nov. 4, 2026 in Cancer
Ichnos Glenmark Innovation (IGI) will present updated clinical data for ISB 2001, an investigational trispecific T-cell engager, as an oral presentation on December 12, 2026, at the 68th ASH Annual Meeting in New Orleans. The drug is being developed for relapsed or refractory multiple myeloma.
Why it matters
The presentation will provide updated clinical evidence for a therapy in early-stage development for a difficult-to-treat blood cancer. Its exclusive global licensing agreement with AbbVie, formed in July 2025, signals large-scale commercial interest in the candidate.
The data will come from the Phase 1 TRIgnite-1 study and a Phase 1/2 combination study, with the 4:00-4:15 p.m. CST oral slot on December 12, 2026 serving as the disclosure point. Results such as response rates and adverse events have not yet been released, and the full scope of the data remains unknown until presentation.
The players
Ichnos Glenmark Innovation (IGI)
IGI is a clinical-stage biotechnology company based in New York that develops oncology biologics, including the ISB 2001 trispecific antibody.
AbbVie
AbbVie is a global biopharmaceutical company that holds exclusive worldwide licensing rights to ISB 2001 under its July 2025 agreement with IGI.
Medical College of Wisconsin
The Medical College of Wisconsin is an academic medical institution whose affiliated researcher will deliver the ISB 2001 oral presentation.
The details
ISB 2001 (ABBV-2001) is a trispecific T-cell engager that targets CD38, BCMA, and CD3 to bring together dual-antigen tumor recognition and T-cell immune engagement in one molecule. It was engineered using IGI's proprietary BEAT Multispecific Platform, and the updated data will be presented in New Orleans at the Ernest N. Morial Convention Center by a researcher from the Medical College of Wisconsin.
Timeline
July 2025: IGI and AbbVie formed an exclusive global licensing agreement for the trispecific.
November 4, 2026: IGI announced the upcoming presentation of updated ISB 2001 clinical data.
December 12, 2026, 4:00-4:15 p.m. CST: Oral presentation of ISB 2001 data at the 68th ASH Annual Meeting.
Shifting Treatment Landscape
Multiple myeloma therapies have increasingly moved toward multispecific T-cell engagers, and ISB 2001 joins this class by pairing CD38 and BCMA targeting with CD3-mediated T-cell engagement. The ASH Annual Meeting remains the principal venue where such early-stage hematology data is first presented to the field.
For people living with relapsed or refractory multiple myeloma, the presentation may offer early indications of whether a trispecific T-cell engager could become a future treatment option. Any eventual access would depend on regulatory review and clinical trial outcomes, which are not yet known.
The takeaway
Investigational multispecific antibodies are advancing quickly in multiple myeloma, but readers should watch for the efficacy and safety data that will determine whether ISB 2001 becomes a viable therapy. Early-stage results alone do not establish clinical benefit.
What happens next
Updated ISB 2001 clinical data is scheduled for oral presentation on December 12, 2026, from 4:00 to 4:15 p.m. CST at the 68th ASH Annual Meeting in New Orleans.
Further reading
For background on the disease this candidate targets, explore the Cancer section for more context.
